Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

Wednesday, July 16, 2025

Aptar Pharma has acquired Mod3 Pharma’s clinical trial material manufacturing capabilities, enhancing its support for Phase 1 and 2 drug development. This move strengthens Aptar’s fill-finish services, particularly for inhaled and nasal drugs, and expands its capabilities in dermal, ophthalmic, and injectable delivery. The FDA-inspected Boonton facility aligns with Aptar’s vision to streamline drug delivery from formulation to patient.About Aptar Pharma

Aptar Pharma is part of AptarGroup, Inc. (NYSE:ATR), a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

Media Contact: 
Ciara Jackson 
Aptar Pharma
+49 151 1951 6502
ciara.jackson@aptar.com